Stockhead: Racura Oncology opens Hong Kong site in “cautious” trial rollout
Stockhead: Racura Oncology opens Hong Kong site in “cautious” trial rollout
Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination...
Samso: Who is Racura Oncology (ASX: RAC)? DYOR on Anti-Cancer Innovation and Heart Protection
Samso: Who is Racura Oncology (ASX: RAC)? DYOR on Anti-Cancer Innovation and Heart Protection
Samso’s Noel Ong has compiled the key highlights of Racura Oncology in this note, and outlined the upcoming inflection points for the company. In his analysis, Mr Ong writes: “Most of us have known...
Racura Oncology announces the publication of bisantrene clinical trial
Racura Oncology announces the publication of bisantrene clinical trial
Racura Oncology has announced the results of the Phase 2 clinical trial of RC110 bisantrene for relapsed or refractory acute myeloid leukaemia (AML) has been published in the peer-reviewed British Journal of Haematology, as...
Racura Oncology treats first patient with RC220 in a milestone quarter
Racura Oncology treats first patient with RC220 in a milestone quarter
Racura Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of...
Executive Chairman Dr Pete Smith Joins The Capital Compass to Discuss Breakthrough Cancer Drug RC220
Executive Chairman Dr Pete Smith Joins The Capital Compass to Discuss Breakthrough Cancer Drug RC220
In this exclusive interview with The Capital Compass, Dr. Pete Smith from Racura Oncology discusses the company’s groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety. Watch...
Racura Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Racura Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours. Read the full article...
The Australian: Racura Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian: Racura Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian reports Racura Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full...
ausbiz: Racura to better cancer treatment
ausbiz: Racura to better cancer treatment
Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial...
Racura Oncology launches Phase I RC220 trial in Australia
Racura Oncology launches Phase I RC220 trial in Australia
Racura Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is...
Stockhead reports Racura gets ethics nod for Phase I trial in solid tumour patients
Stockhead reports Racura gets ethics nod for Phase I trial in solid tumour patients
Racura Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via...
